Stock comparison
BIIBvsINSM
Biogen IncvsInsmed Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
BIIB
Biogen Inc
$187.88
+6.91%
Biotechnology$25.8BNASDAQ
INSM
Insmed Inc
$144.48
-26.63%
Biotechnology$35.0BNASDAQ
60-day price, rebased to 100
BIIB +6.64% · INSM -8.45%
Round-by-round
BIIB 4·INSM 2
EdgeBIIB
Valuation upside
+7.40% vs -90.50% to DCF fair value
EdgeINSM
Balance-sheet strength
Altman Z 3.10 vs 9.81
EdgeBIIB
Fundamental quality
Piotroski 6.00 vs 4.00 (of 9)
EdgeBIIB
Growth + margins
Rule-of-40 23.00 vs -92.80
EdgeBIIB
60-day momentum
+6.64% vs -8.45% price return
EdgeINSM
Market-cap liquidity
$25.8B vs $35.0B
Verdict
Across6categories,BIIBtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onBIIBorINSM
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.